N
Google TrendLIONEL MESSI (5000+) — Messi scores twice for Miami in 1st game since Argentina farewell
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lionel messi5000+sydney sweeney2000+miguel vargas1000+ducks vs flames500+matt rife1000+colin farrell200+emily blunt500+boise state vs fresno state2000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Tafasitamab Combined With" (30 stories)

Top Headline Story

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma
Lead StoryOncLivegeneral
Jan 2

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdXh1RWxlcGZ6REJmNklTVG5JenRrdUtqRmt1OWNvQ2FmUHVpdl84ZFVPT2MwamlzZlhWLS1qVzVJUmNUbXVpcElTTkpFNk1KbzFDN3BFdWJGR3M2VTFrd19Va29fVHB1a3BrcnRqdW5kQVRQd1NVWWprdkF1Vjc1SGNiUmI3QUMtZHZSdU5Pb0QzMU5PdnpOemUzS2tkUzE3MVp5UWJpN0x5WENBdUFmaFNvemNRNm5GeUlyNm82bkI?oc=5" target="_blank">Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+16m ago

lionel messi

Messi scores twice for Miami in 1st game since Argentina farewell

Filter stories
2000+16m ago

sydney sweeney

Sydney Sweeney Is Related to Marilyn Monroe

Filter stories
1000+16m ago

miguel vargas

AL Central Notes: Vargas, Tigers Staff, Royals Ballpark

Filter stories
500+16m ago

ducks vs flames

Ducks at Flames projected lineups

Filter stories

Search Results for "Tafasitamab Combined With"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
PR Newswireworld

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQZ0VEeEdicWFGdHJTcDhQQ1JrTEw3YllicDFZQWZETm1PV3Vqa3lFNVlGcU4yN3JGLVU2blRHQmxCZHp1YlhBdmEyV3JucWgyLUh0Y09hWjYyalo5MkozeXlnRlFpT091RmtzS2ZZNHRzZEdDRmFYQlJ0bVJ1Z25SdUtZZFVXd3VQVEEwOWIyQVZaNTNoNlZrM1JLVDBQX21VN0x6WFdWb2N0cG9PaHlwZE9uVlNtaHpQVlJnQmpVSEN1S0pHRnNyN2E5UjN4MnZaU1VYejU4eTVqQVlScnc?oc=5" target="_blank">New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
frontMIND: Results With Tafasitamab Improve PFS 25% Over R-CHOP for High-Risk DLBCL
AJMCgeneral

frontMIND: Results With Tafasitamab Improve PFS 25% Over R-CHOP for High-Risk DLBCL

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNU0hCdjNNMldmUFlHUTcyY296MjlBM2xWbThSdE5ybW9pUVJBSWc2ZlhHa19mY093ZlhIMUVJalh0MmE4UVBtZWJKVFF0Uk1JSG1oOWNsZWJtakNMdlhUY0R2MzluN2haaldyaXNodXBsRDNUOEJwWDRrOXBubTV0LU9aZm4zenVFRk1YZzRUbzIxejZ1eGo1Q1NnX1VrU2xmb2ZjSlZVaWQwdGc?oc=5" target="_blank">frontMIND: Results With Tafasitamab Improve PFS 25% Over R-CHOP for High-Risk DLBCL</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Incyte reports tafasitamab combo benefit in Phase III frontMIND study
Clinical Trials Arenageneral

Incyte reports tafasitamab combo benefit in Phase III frontMIND study

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQQUw4aVVMMktSX0kyMVZpeGZoOTNJRDViZ250VTJ3bzNZVEVZc1JsbWNNNFgwYUhtRVRwVjdtS2psYW5YZ09iRmJCSllhX1pRTGpPRmlacHdlaEgyaUxNeFVRYzdIZUxadk50TDFMckNudjdxV0VOdzhENEZiVXZocXozT2JiZ2d4QlpiOTgzajZVMDFQ?oc=5" target="_blank">Incyte reports tafasitamab combo benefit in Phase III frontMIND study</a>  <font color="#6f6f6f">Clinical Trials Arena</font>

Read Full StoryMore like this
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Business Wireworld

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

<a href="https://news.google.com/rss/articles/CBMi1wJBVV95cUxPMFJlZnhTNUFhTHdGVHVUWnBKWTg5RUtsMXdHeVV4T3pZbjg4SEJadXl0cXppZEY5dFdwUDJQLWJFWG5RRWZCdUh5NU41OTVocnJfU1ZZTTVDMXRtaFlGY2FTb3ZjTG5mejhBc0ZBNFdlM2lkUHY4MnRmMlk1clN6bUhxUUpCeDVHMFRQZjB5bkltSW9sS2xtSVVtaHJfQ1lTRlZmSDNnNklNVTViQzBhYnFGNVlHdkI0YXF6MUlZcG1iUWE1dXJTd0FuWjRMN3JUdkJXV3JyNU9wb3lZV1M3akxfYkdVUHNxUmQ2V0NLSENFUi04QXk1X0lrRVY5YnY1ZFdZSzJ0WUcwS0o4V3BQX05LZEZ1VkRjdXpmUlBOdmZCSG9mMWJST0tZM0RZQjJVSnVQczZ3a29jNlBjeWdrWmdmRXRLUTZVYnBEZS14UGVhTm1SdjRV?oc=5" target="_blank">Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Tafasitamab Combo Significantly Extends PFS in R/R Follicular Lymphoma
Targeted Oncologygeneral

Tafasitamab Combo Significantly Extends PFS in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNcU1BWUFBcXBVMFZyUFFIeHI1WkZ5azZPZm1hLUtZVmhwZ1B6TWVhMG4tTHNULXVmVWtucDJtV0Z0dDdkRGtURjRKT2NyWlBxT2VvbEF5WVhndER0c3VWNEZjVE9fcXloc1BPQmlsWnQ4cGFadW00ejU0cXpQNVFVbHRyZDdKaGIwVzM2QzhoQ0lZUy1KT0s1SDJLR1Q4RVFCaFQ1aVNB?oc=5" target="_blank">Tafasitamab Combo Significantly Extends PFS in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
European Commission Approves Tafasitamab Combo in R/R Follicular Lymphoma
CancerNetworkworld

European Commission Approves Tafasitamab Combo in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPTXRNM3AtUVlUR1V2RjFvVWdrdk5Da1dpcm1JdU9lUlV3VWpla1dfZUlZYkNmVUJqcFJUWkxUcmtZbFFHWXhROUp0RHMzTXYtV2pqLTNJZXFScDhJdmhMMlF1eTVxb0JHc19oVWpyR3FvazVYSENXWGxQcEpONmlFd1NIRXZFSVg3WFNDOTZXdFZCMW9HYjVQdkZfSWNXREE0cW83cnpOM0V1REtG?oc=5" target="_blank">European Commission Approves Tafasitamab Combo in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
The ASCO Postgeneral

Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMXg2Um4weDRlT0xvamJUR2xQVHczTWpzay1Ec0VkR0ROcnljakNyeVNJbkMySEJxN3pqUmNqOVNoY1A5M2N4TWlKSDhBMnJaLUxyTU5ESUEyQ0dCWnZrYzRaR19mS3dOSVlndk15SXRtYVJIWGIyRUtrSlRlWXNjQzZFLVFSNDJaaElRajNHckhpaGdJNUxqLW9CT29CbThialFHSmpobnRiQm95dHd4Z3d6R0JtZWlIaktCWFhQbFR3OEZJM1k4S1gzN2lwSnAyMUEwTGF0ZktvZGRSZUszWldfcDFxekF6cFRybGVTSjRhZw?oc=5" target="_blank">Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Tafasitamab-Based Regimen Nets Approval in Brazil for R/R Follicular Lymphoma
OncLivegeneral

Tafasitamab-Based Regimen Nets Approval in Brazil for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNRlNHSVdJcFhkQkdGNkY0bmdKdktNV083YlF3eUpCdFNrVFlhLUg2VjFwbmR5ODRCNE1CMjVkSFVtQUdCVldhTC1uZVppMS00Ny1TMkdkYm81LUdiVTNTNWh4OVRkOS0xSGZSdVJaR3FtV2V0LXJnc0hoRlRJa3p3SmM2Q0hwVEd1X2p0MTVvR2hISTA?oc=5" target="_blank">Tafasitamab-Based Regimen Nets Approval in Brazil for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
PR Newswiregeneral

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOejE5Z0RuUjVXVUl0TEJCR1BKVmYycF9rSFRzWHNCLVdNa0NZMFhRVHg5cVdjaGducHdOMTY2YlhZTTFEVXZRS2RaZm04T3hxWmgtcWs5REpJYmRHM2NxR21kZWpxMHN0Y19rY0o2bFpFbHk5ekxwb19jRnJUSnRGZDJVSnBYYWFqc3JER2o4cUJsUGFqQ3JsNTBXa09ESHVjcTVIN2lucDQzWGRiUXloa0lFcUlGbnAyaWdMa3g3N2phOTluZ0RuSkVPQkJhQU5sQU1GdWltclVHdXJz?oc=5" target="_blank">MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Business Wireworld

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

<a href="https://news.google.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?oc=5" target="_blank">Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma
Pharmacy Timesgeneral

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQcE5OQUNEX2VpempTS2tBQ1FHanZzLXJzNWk2TnRreEVwcEM0eUROTDV3ZlpBNnhDdkgtWnQyWVYxa29vYnVGcDg1N1pNS21tZzhiaVk5c1BsME55V3V2OEpGVlRHQUI0NjdwSlpsR1RxaGlrTmlwbWd0amZIc1FyQi10UjJTZ1dYRVFGei1kdm96NXB1THlUcVRoM1YxZ3c1bDg3UVNVakZBRG5GTm9ieWh0YXgxVkQybDhFQ1NMbzZ5YnoxT0dyVXBWWWhBMlFjSk42LTFn?oc=5" target="_blank">Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
FDA Approves Tafasitamab (Monjuvi) Combination for Follicular Lymphoma
Oncology News Centralgeneral

FDA Approves Tafasitamab (Monjuvi) Combination for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMlVZWTVKUWE1a0JKRDMwWi1aalF0QklndWgzQ1Vodm5WZVE2cVh6Ti12alI0dlVlYk4zU1Q0Qk9kbkhmTnkxSjZ1TUk5cS1IXzN5bUdtSTM5aFFjWVZPNnAyTUhzb1B2VnRiaXZWLXAta212Y19EaldIVk9NT1JicGJFa2lrc3RuLVA0QTlhazE3WGZkMlNQM0REd3ZucVNqRFZhc210OWdHXzg?oc=5" target="_blank">FDA Approves Tafasitamab (Monjuvi) Combination for Follicular Lymphoma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma
OncLivegeneral

Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT0g5b1UxcUJNY3hQM0RKLWZRbUdYWFRzZXpKRE5Hdm8zMFlXX0pyczdKbDNvbXMtWlR2MDRKOVlQOVVZblVSQzZvREdiR0FjWWw4S3EwZFhKdUdJdE8yV0tCRm55cnpXZ2Zic3JSamIzbzRPbUNxUEN4OWNOZWx5cHFka09oQVBmMEhtNi1fZ1NNVk14M0pUMWpCUG9sMVhJdDRpUS1oU2V4Q00?oc=5" target="_blank">Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma
The ASCO Postgeneral

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQcmVMMzA4Y2tNMXhpN2hBYUJETnZMMUUwdGRxYWJtWGU5M05MM2FqNEx6dnRUd2xjblhGYk5kRHB4QnF6c0tRajhSNVlQWjhaNHR2SEVJMkltaHRwQTlqeUR1TkNzQWVSdy1teGtMMFkwTjhCOHRIenZJWEcyME1KRE45UkRwdUIxTXRobERDc1FYZ0c2anpKTGkzSnFjeWVDRHQxZG1nLXFKVWJmV3RrMU9SQU10Rm1wc0NNTWI3cFpHVzhOdENBNGlGMllCaWpVc09RZ0Z5QThUaDZ2SFVfN0pCa1hfVkU1TGc?oc=5" target="_blank">Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Business Wireworld

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

<a href="https://news.google.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?oc=5" target="_blank">Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma
CancerNetworkgeneral

FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPZTdkY2pWVUJmUkZRYUl1MF81Z1VEVVRtYm5LS0x5bW41SGVCZFU4RjZ5UHlERTFfa1ZPTGFCUzIwcllYdWJFa0xSS1VVR0ZlM1RWbUl3S0pXTUZKb2JzQ19JbzI5YllUeklFRGtyNmx6RDZTVTVmWHJQOVMwblFTZ3ZtVGt6Snp6SkNfamx6VkZfVWlyM3JF?oc=5" target="_blank">FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Business Wireworld

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMixAJBVV95cUxQVy1UM1JmcUIybEQ4ZWx0TTV3UGtndVVwNTBaTi1Sb1oyRUh0ZzFRS3RDVjRYMmJaUkNuWWptZ2JlUXdCU2g5eVlJamdsb204UzlSNEFEbjF5VEVmc0V3elpCQzUyS2FOM0l2MVJJRXJmNHhMYVFFaXl6aUYwb0thWW5RTVFscXlyakt6TlcyOE9XaDN3OURiOGRKQ0s2M09aSVRuNzBocHY3X3htbTQzbGZjSW9CNEpNUHplTnFnejhwSFR6aGNRUkxma0kyVzFnUV91VnBybjdiTVFfcGdMLVlHamtJYnlDXzZ3RWhYRUpRdXRjVFRSVGFMeUZlRlQ5d3VKUUFuMmtwaHFfSmpVQVBBWDZUOXY4VXZLblk1X0MzV0xuQ3NJYTRKVVVMZ2VBM25HMHpEOHZlbktNckw3bDB0UEI?oc=5" target="_blank">Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma
OncLivegeneral

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxONE1xWU81NmNxS1lsRU1qT3Z4d2hyQjVjTnpua1RCNHVQUElRTENJVEJLQU9oNWtNTU5lQ1JvV1dwZVNLaW53R0d0WDRZMlhvUGhmaUhpb1JlZzdUNTQ0N1NUMDdkRGMtUGdLUXNtVDNDQ0pvY2ZWYmt5YWIzaEs3NzR1YVZaUF9Pb0NDMHBqUTMwZUk5dnFTb0V4YmRMMGJxQU1Ec3VaeWUweU90Q2RKYm9Taw?oc=5" target="_blank">FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL
Lymphoma Hubworld

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPS0tvN2RtWFg4N212QktCQ1VBdG5vekxRWjBYaWhzM1V1YVJteElrdmt5eXNxQ2oxRTlQejdRY2g2eFQxWUFrNVY5d0NFaFBjRVliT2JRUk16VlR5QTY0bDhOUWJlSnlaeWJidUd2LTNZcjFpZUZET3YyMjhHbGNTazQwZnNkbGxCaTVmclM2QVlPWnRhN3BHdmN3QU1YVGFRbUJRQU9GUjI4UmpVQ1E1X2ZCQjlMVHVFcEJRRUZ0V0ZsdnpfSnc?oc=5" target="_blank">Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL
Lymphoma Hubgeneral

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNaHV2NmF0SjNla1oxYkltYjZPcHJTN2U2ODBkbzByMnZaeFItZG1CbnYxWWwycm8zazEyV3BreUJUUEhSOG1XVlFTMEZEd0ZqSGNPUlZ1WFBVZ3pKdnlwUkI5MkRVT0JWV3dKM0N6a19GcHNaOHNYRnlZTHNKU1JqVXVFUW1tU0JtaXd2SWdrbW11YmpoWXM0QlltcEJ3RWJVVS04NzA5UjVObm9YWVRSX1luY3VNSXdCeUFhcTFBR2NoWVJOSENCUm1SNHFQRDNteXJWM1BqeWU5SU5xeUNn?oc=5" target="_blank">Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL
CancerNetworkworld

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN3NsQUl4SUxMWUhkczQwM0tteUFNUnZzSUFYam9RM01YUG5aaDBnejh1c1BnOXJZX3lrT05qWkVNUHJ5ak5oTU5MV1hFbFc2WG95VEtySDJ0bng3LTJiUkdFcDNYcmNRY0J6aWtTOWRiYW9DNll5cHFNMzJCLWNIN19GM05wbGVrR20zRE53aFN6UFNIN2JWZFBJclU4UmRjRms5UEpZZWdWUQ?oc=5" target="_blank">China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL
Lymphoma Hubgeneral

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZUR2QWlYVGJvQmkwblQ0dm9kazdaLTRFYUZwa2gzOVF1YmNnMDJWYzlZOEd6cE9KSUd1R09Dd29SQk9DZnpiVGZDTU8xVS1XNDJwRW9rX0w4UnM4ZlpSTTRKU05HLWpyUnNkWWVVbjBvdGdKRVl2dW5HX2dqWUZJS0hFOHc0dC1vYk9qLXU0ZWJZU3k2Z0hiTmtueXN2dW5nVEU4VG9JZ2FtQVE?oc=5" target="_blank">Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
Adding Tafasitamab to Standard Follicular Lymphoma Regimen Boosts PFS 57%, Study Finds
AJMCgeneral

Adding Tafasitamab to Standard Follicular Lymphoma Regimen Boosts PFS 57%, Study Finds

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPVlBPWjhFUGRyNm5pQTFGZmJaeGs0OGVESUlaREhPTGJnSkxsdXVNdVhTUi1IZXZuLV9sQkpVRDU0UnFKREU4clRZSjNSYVhwYnBjc0lOcHFiam13WTYwZGh2UzZmUXU2NkxDcWFUZnBQMWpZVi1sWEY3MjhyY1lYYTRuQ2c2M3RXcWVyZ2ZQMTRhX3pwcFMzRW1mX3pLckx5c3g1b1N5SkRGQTk4b1E?oc=5" target="_blank">Adding Tafasitamab to Standard Follicular Lymphoma Regimen Boosts PFS 57%, Study Finds</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Tafasitamab Quadruplet Appears Safe, Feasible in Newly Diagnosed DLBCL
CancerNetworkgeneral

Tafasitamab Quadruplet Appears Safe, Feasible in Newly Diagnosed DLBCL

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNRkdscnVxVWlLeUh3cXBxZjJZNU91SFpNQkFRcjhLQzFJdzdWQ1pFcFk4ZTBmNWtzVGpxaUE2NHNIODl4QmRja2lKa1pYbUdUQ3Z4dHZsTFVsLS1seXNIUlRaYnFOQkUxX1JQMXRhQ1p5eGZOLWktVVg1QmtPZk1nSmdYSkVpWGJoYzc0d2pSMlY2LUMyNW5na3Z2X1BocXhRSVRBUnJQaw?oc=5" target="_blank">Tafasitamab Quadruplet Appears Safe, Feasible in Newly Diagnosed DLBCL</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Business Wireworld

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMixAJBVV95cUxPUEhDbndydUdZM3RPOGQxdTdkb2xHUGtsY3NjYlA5ZG9Dc1NLNTRqVTVNM19TLWIxNXFEN3EyWGJPVlc2al9KQVRpMlYxX3pJY3Nia19yU0g4dDBRUFFfOTZvNVlDb3BRV19rU1ZueVZpaGpfZGZDbE5rdDBCcnlLaEJqOWppTEJzZE8yX1hSTE5acFBxYUNOTmFTSUtwY2N2X1BpMkd2WkFFN1dhUm96UnpqOVVzUDdmbE9ZNmp0eWp2N0Zudi0xekFDWWRvb3lsOUNQN2M4dWZyaGl0QnNybEJOdy1qV3o3dnl5T0ZJNnF3dHBqNEhpZUlJVU5DemZaWEN5U0FaeG9LN1FLWGhhTjZNM2RlLVZlNmhSYzBaS0l6MzZiejJUanpoN21TRS1aNUc2TmdEckRZOVZBdUJnMUJRYTg?oc=5" target="_blank">Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?
Lymphoma Hubgeneral

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNNThsR0M3amhtczF2LW9jeTd6R0NPc1ZoWS1hUHl4emlRWjY0UzlHUE80NklIRExEUEdKUFVMUHQzMF9sZlFSODNEOG9yc25WVzdfTUg5NnVIVXdiVjVFQ3hQWHRyejF1Yy1ydnRPX25yenNQQ2RkVkVHbnFaYmtlX2pxOHpKVkRXcUV4WGZqODc3N1BkVlgwbmJhMmNrbnpXNjZDN0xad3VwajRXZ3FyTEFfUzZneFZmYkc2VXVaRV9SWFJjVl9HNw?oc=5" target="_blank">How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL
OncLiveworld

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPTmxUdzBQOUdyWUYzeHYwTWQwYzJsRmFiTjR3M3h1UzRqZ0lkTllheWp2UXM3Smd2NHJfY2FYcUxjOU9vRUpHa1pNNEYwOHl3eF83UEFUSzFMN1R6UE16RUlWVXM2cmh4Q25iU3NEdXJ6bFpsRHN6VzlfaVhVaWlxNUJsTE1mcFl4aFllMlNIVHVuMm5NbE9RbDVZcWhfUmxBcm9PMUZXa2dxWlJiR1gwZGFWV2I1QQ?oc=5" target="_blank">China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Tafasitamab for Follicular Lymphoma
AJMCgeneral

FDA Approves Tafasitamab for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE1Rc2szOTMyVEU5aTduS2Zxc2dGOEZxTV95T2JMZkZXVUVwbzVveTQxOXdVdFBFS1NSYXdOaGtmRkZTZEsza3h2TlE2bzdpX29ObC1vOHFwX2otNHZQTVFONHZtZWpLRkxCMHZDTFVMbXExYUZ5QjZaUVFpQWE3S2c?oc=5" target="_blank">FDA Approves Tafasitamab for Follicular Lymphoma</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL
CancerNetworkgeneral

Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPRGMwaVBQalptQkhRR0oxM0lZTHRYa2Fvc0FXS01XdGxNZHhvclpXREttRGhxa1NuS3kwME1mekZ0bmJKSWozckt0SHRJUXk5Nk5xUGxSZWpqQkYySkdGdXBVb1ZKMGNmVjVWYUpMMXNSMEY2aFdjQ1NkUEIxVGlHNkxqeXNYal9kZEcyZEZwbUJKWFlGUmhwdlNjMmFvWGliSTBKem40dzJLQ2dmSkE?oc=5" target="_blank">Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"Tafasitamab Combined With" — Live Google News Trends & Headlines